Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| LLY | ELI LILLY & Co | 2026-02-18 04:58:53 | 1,041.58 | 5.14 | 0.5 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | 0000059478 | ELI LILLY & Co | US5324571083 | FRDRIPF3EKNDJ2CQJL29 | 350470950 | NYSE | 2834 | Pharmaceutical Preparations | 1231 | IN | LILLY CORPORATE CTR | INDIANAPOLIS | IN | 46285 | UNITED STATES | US | 3172762000 | LILLY CORPORATE CENTER, INDIANAPOLIS, IN, 46285 | LILLY CORPORATE CTR, INDIANAPOLIS, IN, 46285 | LILLY ELI & CO | Pharmaceutical | 1876 | David A. Ricks | 47,000 | https://www.lilly.com/ | 769,792,000,000 | 947,903,000 | 945,383,757 | Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named. | 2026-02-12 15:04:30 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 807,887,000,000 | 38,095,000,000 | 4.9487 | 943,357,420 | -4,812,579 | -0.5076 |
| 2024 | 769,792,000,000 | 371,501,000,000 | 93.2738 | 948,169,999 | -1,994,453 | -0.2099 |
| 2023 | 398,291,000,000 | 123,949,000,000 | 45.1805 | 950,164,452 | -131,666 | -0.0139 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Daniel M. Skovronsky, M.D. | Chief Scientific Officer, President, Executive Vice President | 2024 | 1,430,769 | 0 | 7,499,895 | 3,219,230 | 206,980 | 12,638,744 |
| Anat Hakim | Secretary, Executive Vice President, General Counsel | 2024 | 1,000,000 | 0 | 3,950,071 | 2,250,000 | 66,834 | 7,478,426 |
| David A. Ricks | Chair, Chief Executive Officer, President | 2024 | 1,690,385 | 0 | 19,749,324 | 5,705,049 | 351,685 | 29,242,926 |
| Lucas Montarce | Chief Financial Officer, Executive Vice President | 2024 | 664,639 | 0 | 1,067,135 | 1,114,558 | 39,878 | 2,948,519 |
| Jake Van Naarden | President, Executive Vice President | 2024 | 890,385 | 0 | 2,700,248 | 2,003,366 | 113,062 | 5,773,948 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 50,000 |
| 2024 | 47,000 |
| 2023 | 43,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 65,179,000,000 | 45,042,700,000 | 34,124,100,000 |
| Cost Of Revenue | 11,052,000,000 | 8,418,300,000 | 7,082,200,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 13,337,000,000 | 10,990,600,000 | 9,313,400,000 |
| General And Administrative Expenses | 11,094,000,000 | 8,593,800,000 | 7,403,100,000 |
| Operating Expenses | — | — | — |
| Operating Income | — | — | — |
| Net Income | 20,640,000,000 | 10,590,000,000 | 5,240,400,000 |
| Earnings Per Share Basic | 23 | 11.76 | 5.82 |
| Earnings Per Share Diluted | 22.95 | 11.71 | 5.8 |
| Weighted Average Shares Outstanding Basic | 897,300,000 | 900,605,000 | 900,181,000 |
| Weighted Average Shares Outstanding Diluted | 899,300,000 | 904,059,000 | 903,284,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 7,268,000,000 | 3,268,400,000 | 2,818,600,000 |
| Marketable Securities Current | 16,000,000 | 154,800,000 | 109,100,000 |
| Accounts Receivable | 17,760,000,000 | 11,005,700,000 | 9,090,500,000 |
| Inventories | 13,744,000,000 | 7,589,200,000 | 5,772,800,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 147,000,000 | 111,400,000 | 149,500,000 |
| Total Assets Current | 55,629,000,000 | 32,739,700,000 | 25,727,000,000 |
| Marketable Securities Non Current | 2,802,000,000 | 3,215,900,000 | 3,052,200,000 |
| Property Plant And Equipment | 24,675,000,000 | 17,102,400,000 | 12,913,600,000 |
| Other Assets Non Current | 6,992,000,000 | 5,719,700,000 | 4,989,900,000 |
| Total Assets Non Current | 26,601,000,000 | 18,765,400,000 | 14,500,000,000 |
| Total Assets | 112,476,000,000 | 78,714,900,000 | 64,006,300,000 |
| Accounts Payable | 5,379,000,000 | 3,228,600,000 | 2,598,800,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 1,635,000,000 | 5,117,100,000 | 6,904,500,000 |
| Other Liabilities Current | 8,457,000,000 | 5,051,400,000 | 3,281,300,000 |
| Total Liabilities Current | 35,228,000,000 | 28,376,600,000 | 27,293,200,000 |
| Long Term Debt | 40,868,000,000 | 29,474,000,000 | 19,104,600,000 |
| Other Liabilities Non Current | 3,970,000,000 | 2,178,200,000 | 2,240,600,000 |
| Total Liabilities Non Current | 50,713,000,000 | 36,066,700,000 | 25,849,400,000 |
| Total Liabilities | 85,941,000,000 | 64,443,300,000 | 53,142,600,000 |
| Common Stock | 590,000,000 | 592,400,000 | 593,600,000 |
| Retained Earnings | 24,470,000,000 | 13,545,000,000 | 10,312,300,000 |
| Accumulated Other Comprehensive Income | -2,880,000,000 | -4,321,900,000 | -4,327,000,000 |
| Total Shareholders Equity | 26,535,000,000 | 14,192,100,000 | 10,771,900,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 1,997,000,000 | 1,766,600,000 | 1,527,300,000 |
| Share Based Compensation Expense | 626,000,000 | 645,600,000 | 628,500,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 7,000,000,000 | 2,155,200,000 | 2,451,000,000 |
| Change In Inventories | 4,671,000,000 | 2,507,400,000 | 1,425,000,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | 3,453,400,000 |
| Change In Accounts Payable | 10,187,000,000 | 2,608,800,000 | 4,274,400,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 16,813,000,000 | 8,817,900,000 | 4,240,100,000 |
| Purchases Of Marketable Securities | — | 98,500,000 | 98,200,000 |
| Sales Of Marketable Securities | — | 148,900,000 | 192,200,000 |
| Acquisition Of Property Plant And Equipment | 7,841,000,000 | 5,057,800,000 | 3,447,600,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | -1,000,000 | 298,200,000 | 191,900,000 |
| Cash From Investing Activities | -10,972,000,000 | -9,301,500,000 | -7,152,700,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | 5,384,000,000 | 4,680,400,000 | 4,069,300,000 |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | 4,108,000,000 | 2,500,000,000 | 750,000,000 |
| Issuance Of Long Term Debt | 13,167,000,000 | 11,417,100,000 | 3,958,500,000 |
| Repayment Of Long Term Debt | 778,000,000 | 664,200,000 | 0 |
| Other Financing Activities | -772,000,000 | -490,600,000 | -335,000,000 |
| Cash From Financing Activities | -2,213,000,000 | 1,230,100,000 | 3,495,600,000 |
| Change In Cash | 4,000,000,000 | 449,800,000 | 751,600,000 |
| Cash At End Of Period | 7,268,000,000 | 3,268,400,000 | 2,818,600,000 |
| Income Taxes Paid | 10,814,000,000 | 6,562,100,000 | 5,558,800,000 |
| Interest Paid | 633,000,000 | 577,500,000 | 404,200,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | 23 | 11.76 | 5.82 |
| Price To Earnings Ratio | 46.7252 | 65.6463 | 100.1581 |
| Earnings Growth Rate | 95.5782 | 102.0619 | -16.0173 |
| Price Earnings To Growth Ratio | 0.4889 | 0.6432 | -6.2531 |
| Book Value Per Share | 29.572 | 15.8467 | 12.0684 |
| Price To Book Ratio | 36.3411 | 48.7168 | 48.3015 |
| Ebitda | 34,346,000,000 | 19,699,300,000 | 12,812,400,000 |
| Enterprise Value | 999,545,364,000 | 726,589,760,000 | 547,924,008,520 |
| Dividend Yield | 0.0056 | 0.0067 | 0.0078 |
| Dividend Payout Ratio | 0.2609 | 0.442 | 0.7765 |
| Debt To Equity Ratio | 1.6018 | 2.4373 | 2.4145 |
| Capital Expenditures | 9,569,600,000 | 5,955,400,000 | 4,296,900,000 |
| Free Cash Flow | 7,243,400,000 | 2,862,500,000 | -56,800,000 |
| Return On Equity | 0.7778 | 0.7462 | 0.4865 |
| One Year Beta | 0.6309 | 0.8751 | 0.4408 |
| Three Year Beta | 0.6353 | 0.5705 | 0.517 |
| Five Year Beta | 0.5822 | 0.6615 | 0.6479 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Brown Adrienne S | EVP, President LLY Imm | 2026-02-09 | 1,196 | A | 4,921 |
| Custer Kenneth L. | EVP & President, Card Met Hlth | 2026-02-09 | 659 | A | 10,024 |
| Dozier Eric | EVP, Chief People Officer | 2026-02-09 | 3,512 | A | 14,936 |
| Hakim Anat | EVP, GC & Secretary | 2026-02-09 | 8,277 | A | 22,987 |
| Hernandez Edgardo | EVP & Pres., Mfg. Operations | 2026-02-09 | 4,383 | A | 46,095 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Angus S King, Jr. | Senator | 2026-01-26 | Purchase | 2025-12-29 | Spouse | $1,001 - $15,000 |
| Markwayne Mullin | Senator | 2026-01-16 | Purchase | 2025-12-29 | Joint | $15,001 - $50,000 |
| John Boozman | Senator | 2025-12-08 | Sale (Partial) | 2025-11-21 | Joint | $1,001 - $15,000 |
| Shelley M Capito | Senator | 2025-11-04 | Purchase | 2025-10-24 | Spouse | $1,001 - $15,000 |
| Markwayne Mullin | Senator | 2025-08-12 | Purchase | 2024-12-11 | Joint | $50,001 - $100,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| David J. Taylor | 2026-02-02 | OH02 | Sale | 2026-01-16 | — | $1,001 - $15,000 |
| Julie Johnson | 2026-01-15 | TX32 | Sale | 2025-12-18 | Joint | $1,001 - $15,000 |
| David J. Taylor | 2025-12-19 | OH02 | Sale | 2025-12-10 | — | $1,001 - $15,000 |
| Gilbert Cisneros | 2025-12-15 | CA31 | Purchase | 2025-11-18 | — | $1,001 - $15,000 |
| Julie Johnson | 2025-12-11 | TX32 | Sale (Partial) | 2025-11-13 | Joint | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| CARDIFF PARK ADVISORS, LLC | 2025-12-31 | 882,312 | 821 | 1,074.6797 |
| United Capital Management of KS, Inc. | 2025-12-31 | 13,451,861 | 12,517 | 1,074.6873 |
| Momentous Wealth Management, Inc. | 2025-12-31 | 268,670 | 250 | 1,074.68 |
| GAM Holding AG | 2025-12-31 | 21,709,610 | 20,201 | 1,074.68 |
| HARRIS ASSOCIATES L P | 2025-12-31 | 444,918 | 414 | 1,074.6812 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| VALUE LINE CAPITAL APPRECIATION FUND INC | 2025-12-31 | Institutional | VLIIX | 5,000 | 5,373,400 | 1.0087 |
| VALUE LINE CAPITAL APPRECIATION FUND INC | 2025-12-31 | VALUE LINE CAPITAL APPRECIATION FUND INC | VALIX | 5,000 | 5,373,400 | 1.0087 |
| Value Line Larger Companies Focused Fund, Inc. | 2025-12-31 | Institutional | VLLIX | 4,500 | 4,836,060 | 1.0604 |
| Value Line Larger Companies Focused Fund, Inc. | 2025-12-31 | VALUE LINE LARGER COMPANIES FOCUSED FUND, INC. | VALLX | 4,500 | 4,836,060 | 1.0604 |
| Capital Group Core Balanced ETF | 2025-12-31 | Share Class | CGBL | 31,589 | 33,948,066.52 | 0.7708 |